depending on the residual drug levels at the active site, they also may competitively inhibit metabolism of a simultaneously administered drug
Disclosures: Chady Meroueh: Nothing to Disclose, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor, Neel Patel: PathAI: Employee, Hanna Pulaski: PathAI, Inc: Employee, Lara Murray: Nothing to Disclose, Geetika Singh: PathAI: Employee, PathAI: Employee, Liz Thomas: Nothing to Disclose, Resham Ramkissoon: Nothing to Disclose, Joseph Ahn: Nothing to Disclose, Camille Kezer: Nothing to Disclose, Victoria Kusztos: Nothing to Disclose, Thomas Smith: Nothing to Disclose, Jason Hipp: Nothing to Disclose, Hamid Tizhoosh: Nothing to Disclose, Peyman Nejat: Nothing to Disclose 697 NOVEL ROLE OF LSECS IN HEPATIC IMMUNE FUNCTION DURING SEPSIS TINGTING LI 1 Xuechen Ren 1 Joseph Adams 1 Amy Gravitte 1 Fei Tu 1 David L Williams 1 Chuanfu Li 1 Xiaohui WANG 1 , 1 EAST TENNESSEE STATE UNIVERSITY Background: Sepsis is caused by an uncontrolled host response to infection and is a leading cause of death in intensive care units
They are powerful tools, but they work best when they are part of a larger, intentional lifestyle
However, the optimization of treatment route and dosage requires further research
